Austin, TX -- (SBWIRE) -- 05/02/2013 -- Jackpotpennystocks.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:-
Cereplast Inc(PINK:CERP) shares declined 9.50% to $0.0200. The company on April 30 announced a new bioplastic resin grade Biopropylene A150D, an injection molding grade manufactured with 51% post-industrial algae biomass. The post-industrial algae grade is the first offering with 51% algae content and will be commercially available this quarter. Additionally, the biomass content dramatically reduces the carbon footprint of the final product while reducing the petroleum-based plastic content.
Can CERP Continue To Move Higher? Find Out Here
Cerus Corporation (NASDAQ:CERS) stock decreased 9.40% to $4.82. The company, on April 30, announced financial results for the first quarter ended March 31, 2013. Product revenue for the first quarter of 2013 was $9.7 million, a 12% increase over the first quarter of 2012. Net loss for the first quarter of 2013 was $10.3 million, or $0.17 per share, compared to a net loss of $8.8 million, or $0.17 per share, for the first quarter of 2012.
Can CERS Extend Gain? Find Out Here
Affymetrix, Inc.(NASDAQ:AFFX) shares decreased 9.34% to $3.30. The company on April 30 reported its operating results for the three months ended March 31, 2013. Total revenue was $77.9 million, which included revenue from eBioscience of $19.0 million. GAAP net loss was $15.4 million, or $0.24 per diluted share, as compared to a net loss of $4.2 million, or $0.06 per diluted share, in the first quarter of 2012. Non-GAAP net loss was $0.9 million, or $0.01 per diluted share, as compared to a Non-GAAP net loss of $1.8 million, or $0.03 per diluted share, for the first quarter of 2012.
How Should Investors Trade AFFX Now? Find Out Here
Delcath Systems, Inc. (NASDAQ:DCTH) shares declined 9.01% to $0.757. The company on April 30 announced that the U.S. Food and Drug Administration (FDA) has published on its website the briefing documents for the upcoming May 2, 2013 Oncologic Drugs Advisory Committee (ODAC) meeting.
Additionally, the company announced that it will host a conference call and webcast on Wednesday, May 8, 2013 at 4:30 p.m. ET to discuss the Company's financial results for its 2013 fiscal first quarter ended March 31, 2013, discuss the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) panel votes, and provide an update on recent corporate progress.
How Should Investors Trade DCTH Now? Find Out Here
Jackpotpennystocks.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.
Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.
The assembled information disseminated by Jackpotpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Jackpotpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)